1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole | 170632-50-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole
• 英文别名: 1-Benzyl-3-(5''-hydroxymethylfuryl)-6-fluoroindazole；[5-(1-benzyl-6-fluoro-1H-indazol-3-yl)-furan-2-yl]-methanol；[5-(1-benzyl-6-fluoroindazol-3-yl)furan-2-yl]methanol
• CAS: 170632-50-5
• 化学式: C₁₉H₁₅FN₂O₂
• 分子量: 322.339
• InChiKey: CCXIVOGMSQZBSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole 、 碘甲烷 在 sodium hydride 作用下， 生成 1-Benzyl-6-fluoro-3-(5-methoxymethyl-furan-2-yl)-1H-indazole
  参考文献：
  名称：

  Synthesis of 1-Benzyl-3-(5‘-hydroxymethyl-2‘-furyl)indazole Analogues as Novel Antiplatelet Agents

  摘要：

  1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification. After screening for antiplatelet activity, SARs of YC-1 analogues were established. Among these potent active derivatives, compounds 29, 30, 31, 44, and 45 functioned as potent activators of sGC and inhibitors of PDE5 with potency comparable to that of YC-1. In addition, compound 58 was found to be a selective and potent inhibitor of protease-activated receptor type 4 (PAR4)-dependent platelet activation.

  DOI：

  10.1021/jm010001h
• 作为产物：
  描述：

  2-糠酸甲酯 在 calcium borohydride 、 三氟化硼乙醚 、 三氯化铁 、 溶剂黄146 作用下， 生成 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole
  参考文献：
  名称：

  Synthesis of 1-Benzyl-3-(5‘-hydroxymethyl-2‘-furyl)indazole Analogues as Novel Antiplatelet Agents

  摘要：

  1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification. After screening for antiplatelet activity, SARs of YC-1 analogues were established. Among these potent active derivatives, compounds 29, 30, 31, 44, and 45 functioned as potent activators of sGC and inhibitors of PDE5 with potency comparable to that of YC-1. In addition, compound 58 was found to be a selective and potent inhibitor of protease-activated receptor type 4 (PAR4)-dependent platelet activation.

  DOI：

  10.1021/jm010001h

文献信息

• Novel fused pyrazolyl compound
  申请人：Kuo Sheng-Chu

  公开号：US20050215612A1

  公开（公告）日：2005-09-29

  A fused pyrazolyl compound of the following formula: wherein A, Ar 1 , Ar 2 , R 1 , R 2 , R 3 , and R 4 , are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.

  一种具有下述通式的融合吡唑基化合物：其中A、Ar1、Ar2、R1、R2、R3和R4如本文所定义。还披露了一种含有上述融合吡唑基化合物有效量的药物组合物。
• Method of treating disorders related to protease-activated receptors-induced cell activation
  申请人：——

  公开号：US20020004518A1

  公开（公告）日：2002-01-10

  A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

  一种治疗与蛋白酶激活受体引起的细胞活化相关障碍的方法。该方法包括向需要的受试者施用具有吡唑基核的化合物；通过烷基连接剂与吡唑基核的1-N键合的芳基团；在吡唑基核的4-C和5-C处融合的第二个芳基团；以及直接与吡唑基核的3-C键合的第三个芳基团。
• Preferential inhibition of release of pro-inflammatory cytokines
  申请人：Yung Shin Pharm. Ind. Co. Ltd.

  公开号：EP1576954A1

  公开（公告）日：2005-09-21

  A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R', nitro, halogen, -C(O)-OR', -C(O)-SR', -C(O)-NR'R", -(CH2)mOR', -(CH2)mSR', -(CH2)mNR'R", -(CH2)mCN, -(CH2)mC(O)-OR', -(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are -O(CH2)mO-, in which each of R' and R", independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-κB with such a compound.

  使用式(I)的融合吡唑基化合物优先抑制释放促炎细胞因子而不是抗炎细胞因子的方法：其中A为R或其中R为H，烷基，芳基，环烷基，杂芳基或杂环烷基；Ar1，Ar2和Ar3中的每一个独立地为苯基，噻吩基，呋喃基或吡咯基；R1，R2，R3，R4，R5和R6中的每一个独立地为R'，硝基，卤素，-C(O)-OR'，-C(O)-SR'，-C(O)-NR'R"，-(CH2)mOR'，-(CH2)mSR'，-(CH2)mNR'R"，-(CH2)mCN，-(CH2)mC(O)-OR'，-(CH2)mC(O)H，或者R1和R2一起，R3和R4一起，或者R5和R6一起为-O(CH2)mO-，其中R'和R"中的每一个独立地为H，烷基，环烷基，芳基，杂芳基，杂环烷基；m为0，1，2，3，4，5或6；n为1，2或3。该发明还涵盖了使用这种化合物抑制NF-κB活性的方法。
• Blockade of voltage dependent sodium channels
  申请人：——

  公开号：US20030171403A1

  公开（公告）日：2003-09-11

  Compounds of formula (1), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.

  式（1）的化合物及其药学上可接受的盐能够阻断电压依赖性钠通道，并且在治疗青光眼和多发性硬化症方面具有用处。
• Treatment of disorder related to low cyclic GMP levels
  申请人：——

  公开号：US20030220385A1

  公开（公告）日：2003-11-27

  Methods of treating a disorder associated with low cGMP levels. The methods include administering to a subject in need thereof an effective amount of a compound having a pyrazolyl core, a first aryl group bonded to 3-C of the pyrazolyl core, and a second aryl group fused at 4-C and 5-C of the pyrazolyl core. Also disclosed are pharmaceutical compositions containing these compounds.

  治疗与低cGMP水平相关的疾病的方法。该方法包括向需要的受试者施用具有吡唑基核、第一芳基基团与吡唑基核的3-C键合，以及第二芳基基团融合在吡唑基核的4-C和5-C处的化合物的有效量。还公开了含有这些化合物的制药组合物。